BGMD Stock Overview
BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
BG Medicine, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.02 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -99.00% |
| 3 Year Change | -100.00% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| BGMD | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -3.7% | -3.1% |
| 1Y | -99.0% | -5.7% | 20.9% |
Return vs Industry: BGMD underperformed the US Life Sciences industry which returned 0.9% over the past year.
Return vs Market: BGMD underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| BGMD volatility | |
|---|---|
| BGMD Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BGMD has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BGMD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Paul Sohmer | www.bg-medicine.com |
BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators.
BG Medicine, Inc. Fundamentals Summary
| BGMD fundamental statistics | |
|---|---|
| Market cap | US$11.00 |
| Earnings (TTM) | -US$6.96m |
| Revenue (TTM) | US$1.57m |
0.0x
P/S Ratio0.0x
P/E RatioIs BGMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGMD income statement (TTM) | |
|---|---|
| Revenue | US$1.57m |
| Cost of Revenue | US$505.00k |
| Gross Profit | US$1.06m |
| Other Expenses | US$8.02m |
| Earnings | -US$6.96m |
Last Reported Earnings
Dec 31, 2015
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did BGMD perform over the long term?
See historical performance and comparison